Clinical study reports safety outcomes of high-dose bedaquiline in drug-resistant tuberculosis, highlighting options for optimized regimens.
Extract Bedaquiline (Bdq) was authorised for the treatment of multidrug-resistant (MDR) tuberculosis (TB) in 2014 in Europe. It is part of the preferred BPaLM regimen (Bdq, pretomanid, linezolid (Lzd), moxifloxacin (Mfx)), of individualised MDR-TB treatment and new MDR-TB regimens recommended by the recently updated World Health Organization guidelines [1]. Most trials aiming to develop new regimens for drug-resistant TB include Bdq, making it the most important drug at present.
No takes yet. Share an insight, caveat, or question.
Peterka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: